

PRESS RELEASE

Most Complete Respiratory Protection

Field trials demonstrate most complete respiratory vaccine leads to superior pig health and performance

September 19, 2016

When it comes to raising pigs, it is important to create a system to produce pigs of uniform size that grow at a similar rate. But, what happens when pigs are showing different feed conversion rates, different signs of disease, and as a result, different rates of growth? Your bottom line starts hurting.

“When developing a management plan to produce uniform pigs, there are often three things that producers and animal health professionals think of: pig comfort, feed conversion, and disease management,” says Dr. Eduardo Fano, DVM, a swine technical manager with Boehringer Ingelheim (BI). Producers know that respiratory diseases can play havoc with growth rates and pig uniformity.

Porcine respiratory disease complex (PRDC) is a multi-pathogen disease that can cost producers more than \$10 per pig.¹ Protection against the most common PRDC pathogens, including porcine reproductive and respiratory syndrome (PRRS), *Mycoplasma hyopneumoniae* (Mhp) and porcine circovirus Type 2 (PCV2) should be included in a barn’s vaccination protocols.

As the first and only USDA-compliant trivalent vaccine to offer licensed protection against PRRS, PCV2 and Mhp in a single syringe, 3FLEX® from BIVI has been proven safe and effective to use in pigs as young as 3 weeks of age.

BIVI conducted a large-scale field study evaluating pigs vaccinated with 3FLEX compared to non-vaccinated controls following a challenge with PCV2 and PRRS. The results of the challenge study showed that 3FLEX provides strong protection against PRRS and PCV2 following disease challenge. In fact, the final body weight of vaccinated pigs was almost 14 pounds more than non-vaccinated controls.²

Dr. Fano recommends producers use 3FLEX, which has been shown to provide protection to pigs challenged with PRRS and PCV2 compared to unvaccinated pen mates. A single injection will reduce time and labor required for vaccination, and will also help reduce animal stress as compared to multiple single-antigen vaccines, or two-dose protocols.

“Producers who are vaccinating are making strides in terms of disease management, but often the stress of multiple shots can negate some of the effectiveness of the vaccine,”² Dr.



Fano says. “3FLEX helps mitigate that stress and the economic losses associated with PRDC.”

References:

- 1 Haden, et al. Assessing production parameters and economic impact of swine influenza, PRRS and *Mycoplasma hyopneumoniae* on finishing pigs in a large production system. AASV. 2012; 75-6.
- 2 Payne, et al. Observations of a licensed trivalent PRDC vaccine for PCV2, M. hyo and PRRS. AASV. 2016; 324.

3FLEX is a registered trademark of Boehringer Ingelheim Vetmedica GmbH. ©2017 Boehringer Ingelheim Vetmedica, Inc.

###

About Boehringer Ingelheim Animal Health

As the second largest animal health business in the world, Boehringer Ingelheim is committed to improving animal health. With more than 10,000 employees worldwide, Boehringer Ingelheim Animal Health has products available in more than 150 markets and a global presence in 99 countries. For more information about Boehringer Ingelheim Animal Health, [click here](#).

Boehringer Ingelheim

Innovative medicines for people and animals have for more than 130 years been what the research-driven pharmaceutical company Boehringer Ingelheim stands for. Boehringer Ingelheim is one of the industry’s top 20 pharmaceutical companies and to this day remains family-owned. Day by day, some 50,000 employees create value through innovation for the three business areas human pharmaceuticals, animal health and biopharmaceutical contract manufacturing. In 2016, Boehringer Ingelheim achieved net sales of around 15.9 billion euros. With more than three billion euros, R&D expenditure corresponds to 19.6 per cent of net sales.

Social responsibility comes naturally to Boehringer Ingelheim. That is why the company is involved in social projects, such as the “Making More Health” initiative. Boehringer Ingelheim also actively promotes workforce diversity and benefits from its employees’ different experiences and skills. Furthermore, the focus is on environmental protection and sustainability in everything the company does.



More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com or in our annual report: <http://annualreport.boehringer-ingelheim.com>.

Media contacts

Kenna Rathai
broadhead.
815.422.0321
krathai@broadheadco.com

Melissa Chesnut
Boehringer Ingelheim Animal Health – U.S. Communications
816.390.5356
melissa.chesnut@boehringer-ingelheim.com